Safeway v. Super. Ct. CA1/3

CourtCalifornia Court of Appeal
DecidedJune 19, 2014
DocketA141505
StatusUnpublished

This text of Safeway v. Super. Ct. CA1/3 (Safeway v. Super. Ct. CA1/3) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Safeway v. Super. Ct. CA1/3, (Cal. Ct. App. 2014).

Opinion

Filed 6/19/14 Safeway v. Super. Ct. CA1/3 NOT TO BE PUBLISHED IN OFFICIAL REPORTS California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

FIRST APPELLATE DISTRICT

DIVISION THREE SAFEWAY, INC., Petitioner, A141505

v. (Alameda County SUPERIOR COURT FOR THE Super. Ct. No. RG11600291) COUNTY OF ALAMEDA, Respondent; KATHLEEN HARDIN and DANE HARDIN, Real Parties in Interest. PALO ALTO FOUNDATION MEDICAL GROUP, INC., Petitioner, A141513 v. SUPERIOR COURT FOR THE (Alameda County COUNTY OF ALAMEDA, Super. Ct. No. RG11600291) Respondent; KATHLEEN HARDIN and DANE HARDIN, Real Parties in Interest. SHARON S. JAMIESON, M.D., Petitioner, A141514

v. (Alameda County THE SUPERIOR COURT OF Super. Ct. No. RG11600291) ALAMEDA COUNTY, Respondent;

1 KATHLEEN HARDIN and DANE HARDIN, Real Parties in Interest.

Due to side effects of a drug prescribed by her physician, real party Kathleen Hardin sustained severe and debilitating injuries. She alleged she was not warned of these potential, serious side effects of the medication by her doctor, petitioner Sharon S. Jamieson, M.D., the medical practice that employs Jamieson—petitioner Palo Alto Foundation Medical Group, Inc. [Medical Group], or by the dispensing pharmacy, petitioner Safeway, Inc. Hardin, together with her husband, real party Dane Hardin (Dane),1 sued various defendants, including petitioners, for negligence and loss of consortium. Petitioners brought separate motions for summary judgment, based on their contention that the complaint was untimely. The superior court denied Jamieson’s and the Medical Group’s summary judgment motions, finding there were triable issues of fact regarding the delayed discovery by Hardin of the cause of her injuries. The court also denied Safeway’s motion for summary judgment, in part, due to Hardin’s delayed discovery of the cause of her injuries and, in part, because it was not established that in all relevant respects, Safeway was a health care provider pursuant to the Medical Injury Compensation Reform Act [MICRA] entitled to protection of the statute of limitations for professional negligence. Petitioners each filed timely petitions for writ of mandate in this court. For purposes of this decision only, we consolidate these petitions because they are based on a common set of facts. There are no material disputed facts concerning the applicability of the statute of limitations. We conclude that Hardin and her

1 For ease of reference and to avoid confusion, we will refer to Mr. Hardin by his first name. We intend no disrespect.

2 husband knew her injuries were caused by her adverse reaction to medication in June 2010. Her complaint was not filed within one year of her discovery and is barred by Code of Civil Procedure section 340.5. We also conclude that Safeway was acting as a health care provider in the events alleged in Hardin’s complaint and entitled to the limitations period in section 340.5. We direct the superior court to vacate its orders denying summary judgment and to issue new and different orders granting the summary judgment motions in favor of each petitioner. FACTUAL AND PROCEDURAL BACKGROUND

Hardin was generally under the care of Jamieson, her primary care physician, from sometime in 2002 through June 29, 2011. On March 31, 2010 Jamieson prescribed a new medication, Lamictal, for Hardin without discussing any of the potential risks or side effects associated with the drug. Hardin filled the prescription with Lamotrigine, the generic form of Lamictal, at a Safeway pharmacy in Santa Cruz. She received a one-page computer print-out at the pharmacy which discussed some possible side effects of the drug such as allergic reactions. The print-out did not mention Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TENs) or other serious or life-threatening risks. The pharmacist gave Hardin no verbal or supplemental warnings other than the computer print-out. Hardin began taking 25 milligrams per day on April 2, 2010, and gradually increased the dosage. On April 21, 2010, Jamieson wrote her a new prescription for 100-milligram tablets. When Hardin filled this second prescription she received from Safeway an identical print-out concerning Lamotrigine that she had previously received. Again she received no verbal or supplemental warnings. On April 25 Hardin began to experience a sense of malaise. The next day she called her work to inform them that she was not well. She has no further memories of what happened until she awoke in the hospital in June 2010. The day

3 after Hardin remembers calling work, her husband, Dane, took her to urgent care in Santa Cruz because her condition seemed to be deteriorating. She had small blotches on her face and chest, and her eyes were bloodshot. The next day she was hospitalized at Dominican Hospital, where she went into a coma. She was diagnosed with SJS, a condition that causes internal and external burn-like rashes. On April 28, 2010 she was transferred to the burn unit of the Santa Clara Valley Medical Center, where she was in a coma from April 28 until sometime in June 2010, while SJS and TENs2 caused organ failure. On July 16, 2010, when discharged from the hospital in Santa Clara, Hardin still had open wounds and was virtually blind, able only to sense light and dark. Hardin testified that once she awoke from the coma she was told in June 2010 that she had SJS and TENs and that those conditions were caused by Lamotrigine. She did not know, however, whether the conditions were common complications from Lamotrigine or had been reported in the literature. Dane, on the other hand, had researched the side effects of Lamotrigine and learned on April 27, 2010, that SJS was a potential side effect, after his wife was seen in the Urgent Care Clinic and was instructed to stop taking the medication immediately. Also, in April 2010 Dr. Berger, a physician at the Santa Clara Valley Medical Center, informed Dane that his wife’s SJS was due to Lamotrigine. In June 2010 Dane told his wife that she had developed SJS due to the Lamotrigine. On July 19, 2011 the Hardins consulted an attorney to find out if pharmaceutical companies had a fund to pay for medical expenses related to adverse drug reactions. The attorney informed them that he was unaware of any such fund, but suggested they consult other counsel to investigate whether they had a viable claim of medical malpractice. It was only after this meeting that Hardin

2 TENs is a life-threatening skin condition in which the top layer of skin, the epidermis, detaches from the lower layers, dermis, all over the body.

4 learned that SJS, TENs and serious and fatal rashes were known risks associated with Lamotrigine. Indeed, she learned sometime after July 2011 that the Food and Drug Administration required “boxed warnings” for Lamotrigine concerning the possibility that SJS and “life threatening rashes” might be caused by the drug. A “boxed warning” is the strongest warning the FDA can require and signifies that studies show a significant risk of serious or life-threatening adverse effects from taking the drug. (21 C.F.R. § 201.57(c)(1).) Boxed warnings were omitted from the print-outs Hardin had been provided by Safeway. The printouts Safeway provided were products of software created by PDX, Inc., which Safeway used to provide patients with monographs containing useful, accurate, and comprehensive information about prescription drugs, including the appropriate warnings.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

West v. Great Western Power Co.
97 P.2d 1014 (California Court of Appeal, 1940)
Norgart v. Upjohn Co.
981 P.2d 79 (California Supreme Court, 1999)
Sanchez v. South Hoover Hospital
553 P.2d 1129 (California Supreme Court, 1976)
Stafford v. Shultz
270 P.2d 1 (California Supreme Court, 1954)
Jolly v. Eli Lilly & Co.
751 P.2d 923 (California Supreme Court, 1988)
Ng v. Superior Court
840 P.2d 961 (California Supreme Court, 1992)
Omaha Indemnity Co. v. Superior Court
209 Cal. App. 3d 1266 (California Court of Appeal, 1989)
American International Underwriters Agency Corp. v. Superior Court
208 Cal. App. 3d 1357 (California Court of Appeal, 1989)
Atienza v. Taub
194 Cal. App. 3d 388 (California Court of Appeal, 1987)
Christ v. Lipsitz
99 Cal. App. 3d 894 (California Court of Appeal, 1979)
Blain v. Doctor's Co.
222 Cal. App. 3d 1048 (California Court of Appeal, 1990)
McGee v. Weinberg
97 Cal. App. 3d 798 (California Court of Appeal, 1979)
Monticello Insurance v. Essex Insurance
162 Cal. App. 4th 1376 (California Court of Appeal, 2008)
Bellamy v. Appellate Department
50 Cal. App. 4th 797 (California Court of Appeal, 1996)
Flowers v. Torrance Memorial Hospital Medical Center
884 P.2d 142 (California Supreme Court, 1994)
Palma v. U.S. Industrial Fasteners, Inc.
681 P.2d 893 (California Supreme Court, 1984)
Leonard v. John Crane, Inc.
206 Cal. App. 4th 1274 (California Court of Appeal, 2012)
Yun Hee So v. Sook Ja Shin
212 Cal. App. 4th 652 (California Court of Appeal, 2013)
Hutton v. Fidelity National Title Co.
213 Cal. App. 4th 486 (California Court of Appeal, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Safeway v. Super. Ct. CA1/3, Counsel Stack Legal Research, https://law.counselstack.com/opinion/safeway-v-super-ct-ca13-calctapp-2014.